Bisulfite-free, base-resolution identification of cytosine modifications
US-2020370114-A1 · Nov 26, 2020 · US
US11306355B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11306355-B2 |
| Application number | US-202117201825-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 15, 2021 |
| Priority date | Jan 8, 2018 |
| Publication date | Apr 19, 2022 |
| Grant date | Apr 19, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
This disclosure provides methods for bisulfite-free identification in a nucleic acid sequence of the locations of 5-methylcytosine, 5-hydroxymethylcytosine, 5-carboxylcytosine and 5-formylcytosine.
Opening claim text (preview).
The invention claimed is: 1. A method for identifying 5-methylcytosine (5mC) or 5-hydroxymethylcytosine (5hmC) in a target nucleic acid comprising the steps of: providing a nucleic acid sample comprising the target nucleic acid; modifying the target nucleic acid comprising the steps of: converting the 5mC and 5hmC in the nucleic acid sample to 5-carboxylcytosine (5caC) and/or 5-formylcytosine (5fC) by contacting the nucleic acid sample with a ten-eleven translocation (TET) enzyme so that one or more 5caC or 5fC residues are generated; and converting the 5caC and/or 5fC to dihydrouracil (DHU) by treating the target nucleic acid with a borane reducing agent to provide a modified nucleic acid sample comprising a modified target nucleic acid; and detecting the sequence of the modified target nucleic acid; wherein a cytosine (C) to thymine (T) transition or a cytosine (C) to DHU transition in the sequence of the modified target nucleic acid compared to the target nucleic acid provides the location of either a 5mC or 5hmC in the target nucleic acid. 2. The method of claim 1 , wherein the borane reducing agent is 2-picoline borane. 3. The method of claim 1 , wherein the step of detecting the sequence of the modified target nucleic acid comprises one or more of chain termination sequencing, microarray, high-throughput sequencing, and restriction enzyme analysis. 4. The method of claim 1 , wherein the TET enzyme is selected from the group consisting of human TET1, TET2, and TET3; murine Tet1, Tet2, and Tet3; Naegleria TET (NgTET); and Coprinopsis cinerea (CcTET). 5. The method of claim 1 , further comprising a step of blocking one or more modified cytosines. 6. The method of claim 5 , wherein the step of blocking comprises adding a sugar to a 5hmC. 7. The method of claim 1 , wherein the method further comprises a step of amplifying the copy number of one or more nucleic acid sequences. 8. A method for chemically modifying a nucleic acid sample comprising the steps of: providing a nucleic acid sample comprising 5-carboxylcytosine (5caC) and/or 5-formylcytosine (5fC); and converting the 5caC and/or 5fC to dihydrouracil (DHU) by treating the nucleic acid with a borane reducing agent to provide a modified nucleic acid sample comprising a modified nucleic acid. 9. The method of claim 8 , wherein the borane reducing agent is selected from the group consisting of 2-picoline borane (pic-BH3), borane, sodium borohydride, sodium cyanoborohydride, and sodium triacetoxyborohydride. 10. The method of claim 8 , wherein the borane reducing agent is 2-picoline borane. 11. The method of claim 8 , further comprising the step of detecting the sequence of the modified nucleic acid. 12. The method of claim 11 , wherein the step of detecting the sequence of the modified nucleic acid comprises one or more of chain termination sequencing, microarray, high-throughput sequencing, and restriction enzyme analysis. 13. The method of claim 11 , wherein the sequencing step provides a quantitative level of one or more cytosine modifications in the nucleic acid sample. 14. The method of claim 8 , wherein the method further comprises a step of amplifying the copy number of one or more nucleic acid sequences.
DNA beta-glucosyltransferase (2.4.1.27) · CPC title
DNA alpha-glucosyltransferase (2.4.1.26) · CPC title
Methylation markers · CPC title
Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes · CPC title
Nucleic acid amplification reactions · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.